UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section  
13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 26,  
2025 Johnson & Johnson (Exact name of registrant as specified in its charter)                                      
                                                                                                  
  New Jersey                         1-3215                     22-1024240                        
  (State or Other Jurisdiction of    -Commission File Number    -IRS Employer Identification No.  
  Incorporation)                                                                                  
                                                                                                  
One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (Address of Principal Executive Offices) Registrant’s 
telephone number, including area code: 732- 524-0400 Check the appropriate box below if the Form 8-Kfiling is      
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:  
                                                                                            
  ☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
                                                                                            
                                                                                             
  ☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
                                                                                             
                                                                                                             
  ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
                                                                                                             
                                                                                                             
  ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  
                                                                                                             
Securities registered pursuant to Section 12(b) of the Act:                                                        
                                                                                                    
  Title of each class               Trading Symbol(s)    Name of each exchange on which registered  
  Common Stock, Par Value $1.00     JNJ                  New York Stock Exchange                    
  1.150% Notes Due November 2028    JNJ28                New York Stock Exchange                    
  3.200% Notes Due June 2032        JNJ32                New York Stock Exchange                    
  1.650% Notes Due May 2035         JNJ35                New York Stock Exchange                    
  3.350% Notes Due June 2036        JNJ36A               New York Stock Exchange                    
  3.550% Notes Due June 2044        JNJ44                New York Stock Exchange                    
                                                                                                    
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the          
Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2of the Securities Exchange Act of 1934 (§240.12b-2of
this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant   
has elected not to use the extended transition period for complying with any new or revised financial accounting   
standards provided pursuant to Section 13(a) of the Exchange Act. ☐                                                
                           
  Item 8.01  Other Events  
                           
On February 26, 2025, Johnson & Johnson (the “Company”) completed the previously announced public offerings of the 
following:                                                                                                         
                                                                                             
  (1)  €600,000,000 aggregate principal amount of 2.700% Notes due 2029 (the “2029 Notes”);  
                                                                                             
                                                                                             
  (2)  €700,000,000 aggregate principal amount of 3.050% Notes due 2033 (the “2033 Notes”);  
                                                                                             
                                                                                               
  (3)  €1,000,000,000 aggregate principal amount of 3.350% Notes due 2037 (the “2037 Notes”);  
                                                                                               
                                                                                                 
  (4)  €700,000,000 aggregate principal amount of 3.600% Notes due 2045 (the “2045 Notes”); and  
                                                                                                 
                                                                                                                   
  (5)  €1,000,000,000 aggregate principal amount of 3.700% Notes due 2055 (the “2055 Notes” and, together with     
       the 2029 Notes, the 2033 Notes, the 2037 Notes and the 2045 Notes, the “Notes”);                            
                                                                                                                   
under the Company’s Registration Statement on Form S-3,Reg. No. 333-269836. In connection with the offering of the 
Notes, the Company entered into an underwriting agreement on February 19, 2025, which is filed as Exhibit 1.1      
hereto (the “Underwriting Agreement”), with Citigroup Global Markets Limited, Deutsche Bank AG, London Branch,     
Goldman Sachs & Co. LLC and the several underwriters named therein (the “Underwriters”), pursuant to which the     
Company agreed to issue and sell the Notes to the Underwriters. The Underwriting Agreement incorporates the        
Underwriting Agreement Standard Provisions (Debt), dated February 18. 2025, which is filed as Exhibit 1.2 hereto.  
                                                 
  Item 9.01  Financial Statements and Exhibits.  
                                                 
                  
  (d)  Exhibits.  
                  
                                                                                                                   
             Description                                                                                           
             Underwriting Agreement, dated February 19, 2025, among Johnson & Johnson and Citigroup Global         
             Markets Limited, Deutsche Bank AG, London Branch, Goldman Sachs & Co. LLC and the several             
  Exhibit    Underwriters named therein.                                                                           
  No.        Underwriting Agreement Standard Provisions (Debt) dated February 18, 2025 (Incorporated by reference  
  1.1        to Exhibit 1.2 to the Current Report on Form 8-K filed by the Company with the Securities and         
  1.2        Exchange Commission on February 20, 2025).                                                            
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────── 
  4.1        Company Order establishing the terms of the Notes.                                                    
  4.2        Form of 2.700% Notes due 2029.                                                                        
  4.3        Form of 3.050% Notes due 2033.                                                                        
  4.4        Form of 3.350% Notes due 2037.                                                                        
  4.5        Form of 3.600% Notes due 2045.                                                                        
  4.6        Form of 3.700% Notes due 2055.                                                                        
  5.1        Opinion of Weil, Gotshal & Manges LLP.                                                                
  5.2        Opinion of Troutman Pepper Locke LLP.                                                                 
  23.1       Consent of Weil, Gotshal & Manges LLP (included in Exhibit 5.1 of this Current Report on Form 8-K).   
  23.2       Consent of Troutman Pepper Locke LLP (included in Exhibit 5.2 of this Current Report on Form 8-K).    
  104        The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.                          
                                                                                                                   
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.                                     
                                                                      
                                    JOHNSON & JOHNSON   (Registrant)  
  Date: February 26, 2025    By:    /s/ Marc Larkins                  
 ──────────────────────────────────────────────────────────────────── 
                                    Marc Larkins                      
                                    Corporate Secretary               
                                                                      
